Literature DB >> 6370418

Generation of phenotypic diversity and progression in metastatic tumor cells.

G L Nicolson.   

Abstract

The emergence of diversified tumor cell subpopulations in malignant neoplasms accounts for their heterogeneous cellular phenotypes and virtually ensures that some tumor cells will ultimately evolve with the most favorable properties for their enhanced abilities to survive, grow, invade and metastasize (tumor progression). The rates of cellular phenotypic diversification appear to vary greatly among different tumors and within the same tumor, and they are probably controlled, at least in part, by cellular instability due to chromosomal defects and random somatic mutational events, the rates of which are known to be higher in more malignant cells, and by epigenetic events, which may vary widely depending on the nature of the tumor cells and their microenvironments. As tumor progression proceeds, the most malignant cell subpopulations appear to lose their responsiveness to changes in tumor microenvironment while maintaining their high rates of phenotypic diversification. Tumor and normal cell-cell and cell-extracellular matrix interactions, as well as tumor cell nutrients, oxygen, hormones, growth factors, inducers and other regulatory molecules provide individual malignant cells with microenvironmental signals that could act through epigenetic cellular modifications, such as DNA methylation, and transcriptional, posttranscriptional, translational and posttranslational controls, or combinations of these. In addition, integration of viral gene sequences or viral modification of host DNA in critical regions could affect phenotypic stability. Finally, manipulation of tumor cells by antitumor therapy can also have profound effects on the rates of phenotypic diversification of the surviving tumor cells. A model for generating cellular phenotypic diversity based on the proposed mechanism for rapid generation of immunoglobulin molecular diversity in B cells may be applicable to malignant cells and to cells in general. In this model the expression and activity of gene products from multigene families are affected by a variety of genetic and epigenetic controlling mechanisms, and alterations in regulatory genes caused by recombination, methylation, mutation, or other changes could lead to differences in gene expression, resulting in widespread quantitative (and perhaps some qualitative) changes in particular gene products or their activities. As they proceed down different pathways of gene expression, each cell would be exposed to continual host selection pressures creating diverse, ever-changing malignant cell-populations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370418     DOI: 10.1007/bf00047691

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  108 in total

1.  Shifts in tumor cell phenotypes induced by signals from the microenvironment. Relevance for the immunobiology of cancer metastasis.

Authors:  V Schirrmacher
Journal:  Immunobiology       Date:  1980-07       Impact factor: 3.144

Review 2.  Cancer metastasis. Organ colonization and the cell-surface properties of malignant cells.

Authors:  G L Nicolson
Journal:  Biochim Biophys Acta       Date:  1982-12-21

Review 3.  The implications of tumor heterogeneity for studies on the biology of cancer metastasis.

Authors:  I R Hart; I J Fidler
Journal:  Biochim Biophys Acta       Date:  1981-08-31

4.  Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate.

Authors:  B E Miller; F R Miller; G H Heppner
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

5.  The area-code hypothesis: the immune system provides clues to understanding the genetic and molecular basis of cell recognition during development.

Authors:  L Hood; H V Huang; W J Dreyer
Journal:  J Supramol Struct       Date:  1977

6.  Genotypic and phenotypic evolution of a murine tumor during its progression in vivo toward metastasis.

Authors:  A E Lagarde; T P Donaghue; J W Dennis; R S Kerbel
Journal:  J Natl Cancer Inst       Date:  1983-07       Impact factor: 13.506

7.  High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb).

Authors:  K Bosslet; V Schirrmacher
Journal:  Int J Cancer       Date:  1982-02-15       Impact factor: 7.396

8.  Prognostic implications of ploidy and proliferative activity in human solid tumors.

Authors:  B Barlogie; D A Johnston; L Smallwood; M N Raber; A M Maddox; J Latreille; D E Swartzendruber; B Drewinko
Journal:  Cancer Genet Cytogenet       Date:  1982-05

9.  Differences in cytotoxic effects of activated murine peritoneal macrophages and J774 monocytic cells on metastatic variants of B16 melanoma.

Authors:  K M Miner; J Klostergaard; G A Granger; G L Nicolson
Journal:  J Natl Cancer Inst       Date:  1983-04       Impact factor: 13.506

10.  Distribution of fibronectin on clonal cell lines of a rat mammary adenocarcinoma growing in vitro and in vivo at primary and metastatic sites.

Authors:  A Neri; E Ruoslahti; G L Nicolson
Journal:  Cancer Res       Date:  1981-12       Impact factor: 12.701

View more
  44 in total

1.  Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: the Metabolic Boyden Chamber.

Authors:  U Pilatus; E Ackerstaff; D Artemov; N Mori; R J Gillies; Z M Bhujwalla
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

Review 2.  Modification of the metastatic potential of tumor cells by drugs.

Authors:  K Takenaga
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

Review 3.  The cellular basis of metastasis.

Authors:  P Ruiz; U Günthert
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 4.  Technical considerations for studying cancer metastasis in vivo.

Authors:  D R Welch
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

Review 5.  Quantitative genetic analysis of tumor progression.

Authors:  V Ling; A F Chambers; J F Harris; R P Hill
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

6.  In vivo selection of human renal cell carcinoma cells with high metastatic potential in nude mice.

Authors:  S Naito; S M Walker; I J Fidler
Journal:  Clin Exp Metastasis       Date:  1989 Jul-Aug       Impact factor: 5.150

Review 7.  Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants.

Authors:  L Larizza; V Schirrmacher
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

8.  Preventing diversification of malignant tumor cells during therapy.

Authors:  G L Nicolson; R Lotan
Journal:  Clin Exp Metastasis       Date:  1986 Oct-Dec       Impact factor: 5.150

9.  Growth, morphologic, and invasive characteristics of early and late passages of a human endometrial carcinoma cell line (RL95-2).

Authors:  P Sundareshan; M J Hendrix
Journal:  In Vitro Cell Dev Biol       Date:  1992 Jul-Aug

Review 10.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.